Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.49 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4786883 | 0.91 | SMN1; SMN2 (0.73) | ALDH1A1POLBMAPTCYP2C9CYP2C19 | |
| SCHEMBL8129380 | 0.83 | ALDH1A1 (0.69) | ALDH1A1POLBMAPTCYP2C9CYP2C19 | |
| SCHEMBL31474229 | 0.83 | ALDH1A1 (1.00) | ALDH1A1POLBMAPTCYP2C9CYP2C19 | |
| SCHEMBL21382574 | 0.83 | SMN1; SMN2 (0.84) | ALDH1A1POLBMAPTCYP2C9CYP2C19 | |
| SCHEMBL28453160 | 0.83 | POLB (0.69) | ALDH1A1POLBMAPTCYP2C9CYP2C19 | |
| SCHEMBL15382481 | 0.83 | ALDH1A1 (0.69) | ALDH1A1POLBMAPTCYP2C9CYP2C19 | |
| SCHEMBL11809969 | 0.83 | POLB (0.69) | ALDH1A1POLBMAPTCYP2C9CYP2C19 | |
| SCHEMBL22576723 | 0.83 | ALDH1A1 (0.69) | ALDH1A1POLBMAPTCYP2C9CYP2C19 | |
| SCHEMBL5251522 | 0.82 | MAPT (0.70) | ALDH1A1POLBMAPTCYP2C9CYP2C19 | |
| SCHEMBL15038459 | 0.82 | ERCC1 (0.54) | ALDH1A1POLBMAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3966758-A | Anti-inflammatory 1-(substituted benzyl)-2-imidazolidinones | MORTON-NORWICH PRODUCTS, INC. (US) | 1976-06-29 | — | — | US | claimed |
| EP-4737448-A1 | SARM1 ENZYME ACTIVITY INHIBITOR AND USE THEREOF | Artivila (ShenZhen) Innovation Center, Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025002030-A1 | SARM1 ENZYME ACTIVITY INHIBITOR AND USE THEREOF | 科辉智药(深圳)新药研究中心有限公司 | 2025-01-02 | — | — | WO | disclosed |
| US-20230303544-A1 | LMO2 PROTEIN INHIBITORS | UNIV OF OXFORD (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20230303544-A1 | LMO2 PROTEIN INHIBITORS | UNIV OF OXFORD (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20230303544-A1 | LMO2 PROTEIN INHIBITORS | UNIV OF OXFORD (GB) | 2023-09-28 | — | — | US | disclosed |
| EP-4200284-A1 | LMO2 PROTEIN INHIBITORS | University of Oxford (GB) | 2023-06-28 | — | — | EP | disclosed |
| WO-2022038356-A1 | LMO2 PROTEIN INHIBITORS | UNIVERSITY OF OXFORD (GB) | 2022-02-24 | — | — | WO | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-102532162-A | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2012-07-04 | — | — | CN | disclosed |
| WO-2008136754-A1 | NOVEL BENZYL - 2 -OXO-PIPERAZINYL/ 7-OXO/5-OXA- [1,4] DIAZEPANYL/ 2 -OXO- TETRAHYDROPYRIMIDINYL DERIVATIVES | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-3966758-A | Anti-inflammatory 1-(substituted benzyl)-2-imidazolidinones | MORTON-NORWICH PRODUCTS, INC. (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303544-A1 | LMO2 PROTEIN INHIBITORS | LMNB2, LMNB1, TPX2 | ALDH1A1 3524/4885POLB 2249/4885MAPT 2968/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ALDH1A1 355/4885POLB 1637/4885MAPT 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.